Linnaeus Therapeutics announces clinical trial collaboration agreement with Merck to evaluate LNS8801 in combination with KEYTRUDA

Linnaeus Therapeutics, Inc., a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that it has entered into a clinical collaboration agreement with Merck to evaluate the combination of its lead investigational product candidate LNS8801, and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with selected advanced solid tumors.

Read More

Skip to content